ASX lifts as Trump flips; Bellevue Gold sinks
ASX inches higher on US tariff buzz, Bellevue cops a hit after a big cap raise, and HUB24 steals the spotlight with record inflows.
ASX inches higher on US tariff buzz, Bellevue cops a hit after a big cap raise, and HUB24 steals the spotlight with record inflows.
Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate.
Meteoric has added tonnes to its Brazilian portfolio, making it one of the highest grade ionic clay rare earth deposits globally.
Strength in the energy sector coupled with strong gold prices have lifted the ASX about 0.3pc in early morning trading.
Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs to have in your portfolio.
Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key player.
Neuren Pharmaceuticals and US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue, exceeding expectations of two years ago when the drug was approved in the US.
Several ASX companies are developing and providing technologies for reliable communications in remote areas, including Harvest Technology.
The US Food & Drug Administration has approved EBR System’s leadless pacemaker WISE, the only device able to deliver left-ventricle stimulation.
EBR Systems lands FDA approval for Wise CRT system, a world first solution proving pacing options for the left side of the heart.
ASX jumps on tariff relief, Wall Street ends strongly despite “Sell America” talk and Neuren and GGE take off.
Koonenberry Gold has lifted 30pc on broad, high-grade results from the second diamond hole at Sunnyside prospect.
After last week’s chaos investors are breathing a sigh of relief today, buying into a marginally calmer market and driving the ASX up 1.5pc.
Argonaut’s David Franklyn unpacks the key strategies he uses to get ahead in a market downturn, and his junior stock of the month.
If it feels like the global economy is burning that could be a hint that gold equities are about to outperform again.
Check out the top 10 winners and losers on the ASX as miners buoy the market. US and Asian markets lifted over the past five days despite tariff chaos.
Finder Energy shows how serious Timor-Leste is about attracting resources investment and why the jurisdiction stands out from the pack.
Nordic Resources has completed an oversubscribed placement to advance its new gold and copper asset in Finland.
In the spirit of hopeless optimism, here are seven reasons why Australia could fare well in the redux world of tariff protectionism.
Major Chilean lithium producer SQM is going ahead with Chilean deal with Codelco to extract lithium from the Atacama salt flat.
Trump’s tariffs are shaking things up worldwide, but small-cap Aussie utilities might just sail through and even come out ahead.
ASX gold explorer Arika is chasing more elephants in the elephant country of Laverton in WA’s Goldfields. And the market is taking notice.
Antimony stocks weren’t saved from the recent market carnage. But prices are at all time highs and advanced players are now looking cheap.
ASX health stocks fall with Morgans Scott Power noting Trump’s on-again, off-again Liberation Tariffs sending shock waves through markets.
The ASX has dipped 0.82pc in trading today, while gold soared to record new highs above US$3,200 per ounce and oil fell to levels not seen since March 2020.
Original URL: https://www.theaustralian.com.au/business/stockhead/news